Granules India said on Thursday that it has received licence from Defence Research and Development Organisation (DRDO) to manufacture and market COVID-19 treatment drug, 2- Deoxy-D-Glucose (2-DG).
Developed by DRDO, 2-DG has been granted permission by Drug Controller General of India (DCGI) for emergency use as adjunct therapy in moderate to severe COVID-19 patients, Granules India said in a filing to BSE.
“Granules is working closely with DRDO team to launch the product in India at the earliest,” it added.
The drug reduces a patient’s average recovery time by two and half days and oxygen demand by up to 40 per cent, the filing said.
Sleep is often regarded as a luxury in today’s fast-paced world, but scientific research continuously…
Heart disease remains one of the leading causes of death worldwide, and in India, cardiovascular…
Delhi is witnessing a sharp rise in flu cases, particularly Influenza B and H1N1 (commonly…
In early February 2025, a tragic incident occurred in Eluru, Andhra Pradesh, where a 61-year-old…
Holi, the festival of colors, is one of the most vibrant and joyous celebrations in…
In a major development, the U.S. Food and Drug Administration (FDA) has issued recalls for…